BioRestorative Therapies (BRTX) said Thursday that the US Food and Drug Administration has cleared its investigational new drug application for BRTX-100 to potentially treat chronic cervical discogenic pain.
BioRestorative Chief Executive Officer Lance Alstodt said the company is planning to carry out a phase 2 study to evaluate BRTX-100's safety and preliminary efficacy in patients with chronic cervical discogenic pain "as soon as is practicable."
Price: 1.87, Change: -0.04, Percent Change: -2.09
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。